

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAVXR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 DEC 01 ChemPort single article sales feature unavailable  
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances  
enhanced  
NEWS 4 APR 07 STN is raising the limits on saved answers  
NEWS 5 APR 24 CA/CAPLUS now has more comprehensive patent assignee  
information  
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent  
assignment/reassignment information  
NEWS 7 APR 28 CAS patent authority coverage expanded  
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced  
NEWS 9 APR 28 Limits doubled for structure searching in CAS  
REGISTRY  
NEWS 10 MAY 08 STN Express, Version 8.4, now available  
NEWS 11 MAY 11 STN on the Web enhanced  
NEWS 12 MAY 11 BEILSTEIN substance information now available on  
STN Easy  
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased  
limits for exact sequence match searches and  
introduction of free HIT display format  
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal  
status data  
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in  
records back to 1992  
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching  
enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:54:15 ON 17 JUN 2009

=> file registry  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 17 JUN 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2009 HIGHEST RN 1158168-92-3  
DICTIONARY FILE UPDATES: 15 JUN 2009 HIGHEST RN 1158168-92-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\vrodriguezgarci\My Documents\e-Red  
Folder\10586573\L1.str



chain nodes :  
7 8 9 10 11 13 14 15 16 17  
ring nodes :  
1 2 3 4 5 6 12 18 19 20 21 22  
chain bonds :  
6-7 7-8 7-11 8-9 9-10 10-15 11-12 11-13 13-14 13-16 16-17  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 12-18 12-22 18-19 19-20 20-21 21-22

exact/norm bonds :  
 7-11 8-9 9-10 10-15 13-14 13-16 16-17  
 exact bonds :  
 6-7 7-8 11-12 11-13  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 12-18 12-22 18-19 19-20 20-21 21-22  
 isolated ring systems :  
 containing 1 : 12 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:CLASS 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom  
 19:Atom 20:Atom 21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> s sam sss l1

SAMPLE SEARCH INITIATED 10:55:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 257 TO 903

PROJECTED ANSWERS: 4 TO 200


L2 4 SEA SSS SAM L1

=> d sca

L2 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid,  $\alpha$ -[2-[[4-(acetyloxy)-2-(3-fluorophenyl)-4-methyl-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-penten-1-yl]oxy]-2-methyl-1-[4-(methylsulfonyl)phenyl]propylidene]-3-fluoro-, sodium salt (1:1)


MF C40 H38 F2 O10 S2 . Na



● Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-[[4-(acetyloxy)-2-(3-fluorophenyl)-4-methyl-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-penten-1-yl]oxy]-2-methyl-1-[4-(methylsulfonyl)phenyl]propylidene]-3-fluoro-  
MF C40 H38 F2 O10 S2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-[[[4,5-bis(nitrooxy)pentyl]oxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)-  
MF C25 H28 N2 O13 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[1-[4-(aminosulfonyl)phenyl]-2-(benzoyloxy)ethylidene]-, methyl ester, (Z)- (9CI)  
MF C24 H21 N O6 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s full sss l1

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 11:12:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 767 TO ITERATE

100.0% PROCESSED 767 ITERATIONS

84 ANSWERS

SEARCH TIME: 00.00.01

L3 84 SEA SSS FUL L1


=> d sca

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Ethanaminium, 2-[[4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-

MF C24 H28 F2 N O6 S


CI COM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-hydroxyhexyl ester, ( $\alpha Z$ )-  
 MF C25 H30 O7 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-1-oxohexyl]oxy]ethylidene]-, 2-(diethylamino)ethyl ester, ( $\alpha Z$ )-  
 MF C29 H38 N2 O9 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Ethanaminium, 2-[[ (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-  
1-oxo-4-[[ (2R)-1-oxo-2-propyloctyl]oxy]-2-buten-1-yl]oxy]-N,N,N-trimethyl-  
, bromide (1:1)  
MF C33 H46 F2 N O6 S . Br


Absolute stereochemistry.  
Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 4,5-bis(nitrooxy)pentyl ester,  
( $\alpha$ Z)-  
MF C24 H26 N2 O12 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, ( $\alpha$ Z)-  
 MF C25 H29 N O9 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-,  
 3-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]propyl ester,  
 ( $\alpha$ Z)-  
 MF C28 H31 F N2 O9 S2

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN L-Aspartic acid, 4-[(2Z)-3-(3,4-difluorophenyl)-4-ethoxy-2-[4-(methylsulfonyl)phenyl]-4-oxo-2-buten-1-yl] ester  
MF C23 H23 F2 N O8 S


Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 3-carboxy-2-[4-(methylsulfonyl)phenyl]-3-phenyl-2-propen-1-yl ester  
MF C36 H32 O10 S2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-[[4-(4-bromobutoxy)carbonyloxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
MF C23 H25 Br O7 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(benzoyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, (Z)- (9CI)  
 MF C25 H22 O6 S


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-, bromide (1:1)  
 MF C24 H29 F N O6 S . Br



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,  
 (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-  
 phenyl-2-buten-1-yl ester  
 MF C30 H38 N2 O11 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[6-  
 (nitrooxy)hexyl]oxy]carbonyl]oxy]ethylidene]-, ethyl ester, ( $\alpha$ Z)-  
 MF C26 H31 N O10 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[ (2Z)-2-(3,4-difluorophenyl)-4-[[ (3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl]oxy]-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-  
 MF C36 H42 F2 N O8 S


Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, (5R)-5,6-bis(nitrooxy)hexyl ester, ( $\alpha$ Z)-  
 MF C25 H28 N2 O12 S

Absolute stereochemistry.  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[3-(bromomethyl)benzoyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C26 H23 Br O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-2-methyl-1-[4-(methylsulfonyl)phenyl]propylidene]-3-fluoro-, methyl ester, ( $\alpha$ Z)-  
 MF C22 H23 F O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, ( $\alpha$ Z)-,  
 (2S)-2-amino-3-ethoxy-3-oxopropyl ester, 2,2,2-trifluoroacetate (1:1)  
 MF C24 H25 F2 N O8 S . C2 H F3 O2

CM 1

Absolute stereochemistry.  
 Double bond geometry as shown.




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[4-(acetyloxy)-2-(3-fluorophenyl)-4-methyl-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-penten-1-yl]oxy]-2-methyl-1-[4-(methylsulfonyl)phenyl]propylidene]-3-fluoro-, sodium salt (1:1)  
 MF C40 H38 F2 O10 S2 . Na



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]benzoyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C32 H38 O7 S Si

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, (Z)- (9CI)  
MF C20 H20 O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, (2S)-2-amino-3-ethoxy-3-oxopropyl ester  
MF C24 H25 F2 N O8 S

Absolute stereochemistry.  
Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,  
 (2Z)-4-[(6-bromohexyl)oxy]-2-[4-(methylsulfonyl)phenyl]-4-oxo-3-phenyl-2-  
 buten-1-yl ester  
 MF C30 H38 Br N O8 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[6-(  
 nitrooxy)hexyl]oxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C25 H29 N O10 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

```
L3      84 ANSWERS      REGISTRY  COPYRIGHT 2009 ACS on STN
IN      1H-Benzimidazole-4-carboxylic acid,
        2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-,
        (2Z)-3-(3,4-difluorophenyl)-4-ethoxy-2-[4-(methylsulfonyl)phenyl]-4-oxo-2-
        buten-1-yl ester
MF      C43 H36 F2 N6 O7 S
```

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5,6-bis(nitrooxy)hexyl ester, ( $\alpha Z$ )-  
MF C25 H28 N2 O12 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]benzoyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ E)-  
 MF C32 H38 O7 S Si

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(aminosulfonyl)phenyl]ethylidene]-4-fluoro-, methyl ester, (Z)- (9CI)  
 MF C19 H18 F N O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-,  
 (2S)-2-amino-3-ethoxy-3-oxopropyl ester, ( $\alpha$ Z)-  
 MF C24 H25 F2 N O8 S  
 CI COM


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-,  
 3-carboxy-2-[4-(methylsulfonyl)phenyl]-3-phenyl-2-propen-1-yl ester,  
 sodium salt (1:1)  
 MF C36 H32 O10 S2 . Na




● Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenecetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[3-  
 [(nitrooxy)methyl]phenoxy]carbonyl]oxy]ethylidene]-, methyl ester,  
 ( $\alpha$ Z)-  
 MF C26 H23 N O10 S


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid,  $\beta$ -[(1-oxopropoxy)methyl]- $\alpha$ -phenyl-,  
 ethyl ester  
 MF C21 H24 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Ethanaminium, 2-[[4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-, bromide (1:1)  
MF C24 H28 F2 N O6 S . Br



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-bromohexyl ester, ( $\alpha$ Z)-  
MF C25 H29 Br O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[4-(nitroxy)butoxy]carbonyl]oxy]ethylidene]-, ethyl ester, ( $\alpha$ Z)-

MF C24 H27 N O10 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN


IN 1H-Benzimidazole-7-carboxylic acid,  
2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-,  
3-[[ (2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-  
oxo-2-buten-1-yl]oxy]-2-oxopropyl ester

MF C46 H39 F N6 O10 S

Double bond geometry as shown.

PAGE 1-A






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[2,3-bis(nitrooxy)propoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, phenylmethyl ester, ( $\alpha$ Z)-  
 MF C28 H26 N2 O13 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[3-(bromomethyl)phenoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C26 H23 Br O7 S

Double bond geometry as shown.






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(aminosulfonyl)phenyl]ethylidene]-3,4-difluoro-, methyl ester, (Z)- (9CI)  
 MF C19 H17 F2 N O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[ (2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-  
 MF C24 H29 F N O6 S  
 CI COM

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methanesulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-1-[4-(methanesulfonyl)phenyl]ethylidene]-3,4-difluoro-  
 MF C36 H28 F4 O10 S2  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methanesulfonyl)phenyl]-2-[[[5-(nitroxy)pentyl]oxy]carbonyl]oxy]ethylidene]-, 2-(diethylamino)ethyl

ester, hydrochloride (1:1), ( $\alpha$ Z)-  
 MF C29 H38 N2 O10 S . Cl H

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[4-[(2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-  
 4-methyl-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-penten-1-yl]oxy]-1-  
 oxobutoxy]-2-methyl-1-[4-(methylsulfonyl)phenyl]propylidene]-3-fluoro-,  
 ( $\alpha$ Z)-  
 MF C44 H44 F2 O12 S2  
 CI COM

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-[[ (2S)-2,6-diamino-1-oxohexyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, monoethyl ester (9CI)  
MF C25 H30 F2 N2 O6 S

Absolute stereochemistry.  
Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-buten-1-yl ester  
MF C25 H30 N2 O9 S  
CI COM

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-  
1-oxohexyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
MF C24 H27 N O9 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-,  
(2S)-2-[[1-(1,1-dimethylethoxy)carbonyl]amino]-3-ethoxy-3-oxopropyl ester,  
( $\alpha$ Z)-  
MF C29 H33 F2 N O10 S

Absolute stereochemistry.  
Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[2,3-bis(nitrooxy)propoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha Z$ )-  
 MF C23 H24 N2 O13 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[3-(hydroxymethyl)phenoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha Z$ )-  
 MF C26 H24 O8 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(aminosulfonyl)phenyl]-2-(benzoyloxy)ethylidene]-, methyl ester, (Z)- (9CI)  
 MF C24 H21 N O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[[(2Z)-4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-  
 MF C24 H28 F2 N O6 S  
 CI COM

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methanesulfonyl)phenyl]ethylidene]-3,4-difluoro-,  
 3-(3,4-difluorophenyl)-4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-[4-(methanesulfonyl)phenyl]-2-buten-1-yl ester  
 MF C42 H44 F4 O9 S2 Si




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[5-(nitrooxy)pentyl]oxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C24 H27 N O10 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED  
 MF C44 H44 F2 O12 S2 . Na

Double bond geometry as shown.




● Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[(2S)-2-amino-3-hydroxy-1-oxopropoxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, monoethyl ester (9CI)  
 MF C22 H23 F2 N O7 S

Absolute stereochemistry.  
 Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 7-(nitrooxy)heptyl ester, ( $\alpha$ Z)-  
 MF C26 H31 N O9 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[4-(nitrooxy)butoxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-

MF C23 H25 N O10 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Ethanaminium, 2-[[[(2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-, bromide  
(1:1)  
MF C24 H29 F N O6 S . Br

Double bond geometry as shown.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-[[[4,5-

bis(nitrooxy)pentyl]oxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)-  
 MF C25 H28 N2 O13 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]phenoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C32 H38 O8 S Si

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(aminosulfonyl)phenyl]ethylidene]-, methyl ester, (Z)- (9CI)  
MF C19 H19 N O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 1,6-hexanediyl ester, ( $\alpha$ Z, $\alpha'$ Z)- (9CI)  
MF C44 H46 O12 S2

Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-[4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, sodium salt (1:1)  
MF C36 H28 F4 O10 S2 . Na



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-  
 1-oxohexyl]oxy]ethylidene]-, (1S)-1-carboxyethyl ester, ( $\alpha$ Z)-  
 MF C26 H29 N O11 S

Absolute stereochemistry.  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[[(2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-4-[[[(2R)-1-oxo-2-propyloctyl]oxy]-2-buten-1-yl]oxy]-N,N,N-trimethyl-  
 MF C33 H46 F2 N O6 S  
 CI COM


Absolute stereochemistry.  
 Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN L-Aspartic acid, 4-[3-(3,4-difluorophenyl)-4-ethoxy-2-[4-(methylsulfonyl)phenyl]-4-oxo-2-buten-1-yl] ester  
 MF C23 H23 F2 N O8 S

Absolute stereochemistry.  
 Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-

(methylsulfonyl)phenyl]ethylidene]-, 5-(nitrooxy)pentyl ester, ( $\alpha$ Z)-  
 MF C24 H27 N O9 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[3-  
 [(nitrooxy)methyl]benzoyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C26 H23 N O9 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[[(2Z)-4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(  
 (methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-, bromide  
 (1:1)  
 MF C24 H28 F2 N O6 S . Br




Double bond geometry as shown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[4,5-  
 bis(nitrooxy)pentyl]oxy]carbonyl]oxy]-1-[4-  
 (methylsulfonyl)phenyl]ethyldene]-, methyl ester, ( $\alpha$ Z)-  
 MF C24 H26 N2 O13 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[(6-bromohexyl)oxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)-  
 MF C26 H31 Br O7 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-, methyl ester, (Z)- (9CI)  
 MF C20 H19 F O6 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Ethanaminium, 2-[[[4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-


MF C24 H29 F N O6 S  
CI COM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[5-(nitrooxy)pentyl]oxy]carbonyl]oxy]ethylidene]-, 2-(diethylamino)ethyl ester, ( $\alpha$ Z)-  
MF C29 H38 N2 O10 S  
CI COM

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[6-(nitrooxy)-1-oxohexyl]oxy]ethylidene]-, (1S)-2-(1,1-dimethylethoxy)-1-methyl-2-oxoethyl ester, ( $\alpha$ Z)-  
MF C30 H37 N O11 S

Absolute stereochemistry.  
Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid, 3,4-difluoro- $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-  
 [[(2R)-1-oxo-2-propyloctyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-  
 MF C29 H36 F2 O6 S

Absolute stereochemistry.  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(  
 methylsulfonyl)phenyl]ethylidene]-, 3,4-bis(nitrooxy)butyl ester,  
 ( $\alpha$ Z)-  
 MF C23 H24 N2 O12 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester, monohydrochloride (9CI)  
 MF C25 H30 N2 O9 S . Cl H

Double bond geometry as shown.




● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-, 2-[1-methyl-4-(nitrosothio)-4-piperidinyl]ethyl ester, ( $\alpha$ Z)-  
 MF C27 H31 F N2 O7 S2

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[(2S)-2,6-diamino-1-oxohexyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, monoethyl ester, ( $\alpha E$ )-(9CI)  
 MF C25 H30 F2 N2 O6 S

Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid,  $\alpha$ -[2-[[[4-(acetyloxy)-2-(3-fluorophenyl)-4-methyl-

3-[4-(methylsulfonyl)phenyl]-1-oxo-2-penten-1-yl]oxy]-2-methyl-1-[4-(methylsulfonyl)phenyl]propylidene]-3-fluoro-

MF C40 H38 F2 O10 S2

CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid,  $\alpha$ -[2-[[4-(bromobutoxy)carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)-

MF C24 H27 Br O7 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 84 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, methyl ester, (Z)- (9CI)

MF C20 H18 F2 O6 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file zcaplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
201.24	201.46

FILE 'ZCAPLUS' ENTERED AT 11:14:23 ON 17 JUN 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 17 Jun 2009 VOL 150 ISS 25  
 FILE LAST UPDATED: 15 Jun 2009 (20090615/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e us2006-586573/apps  
 E1 1 US2006-586565/AP  
 E2 2 US2006-586567/AP



```

E3          1 --> US2006-586573/AP
E4          0      US2006-586573/PRN
E5          1      US2006-586574/AP
E6          1      US2006-586575/AP
E7          1      US2006-586576/AP
E8          1      US2006-586577/AP
E9          1      US2006-586578/AP
E10         1      US2006-586579/AP
E11         1      US2006-586581/AP
E12         1      US2006-586583/AP

```

```

=> s us2006-586573/apps
      1 US2006-586573/AP
      0 US2006-586573/PRN
L4      1 US2006-586573/APPS
      (US2006-586573/AP,PRN)

```

```

=> sel rn
E1 THROUGH E34 ASSIGNED

```

```

=> file registry
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                5.90      207.36

```

FILE 'REGISTRY' ENTERED AT 11:15:49 ON 17 JUN 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

```

STRUCTURE FILE UPDATES:   15 JUN 2009   HIGHEST RN 1158168-92-3
DICTIONARY FILE UPDATES:  15 JUN 2009   HIGHEST RN 1158168-92-3

```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```

=> s e1-e34
      1 10102-43-9/BI
      (10102-43-9/RN)
      1 108-24-7/BI
      (108-24-7/RN)
      1 122-04-3/BI
      (122-04-3/RN)
      1 14739-12-9/BI
      (14739-12-9/RN)
      1 14739-15-2/BI
      (14739-15-2/RN)
      1 14739-16-3/BI

```

(14739-16-3/RN)  
 1 14739-18-5/BI  
 (14739-18-5/RN)  
 1 14739-19-6/BI  
 (14739-19-6/RN)  
 1 162011-90-7/BI  
 (162011-90-7/RN)  
 1 179174-76-6/BI  
 (179174-76-6/RN)  
 1 179174-77-7/BI  
 (179174-77-7/RN)  
 1 179174-79-9/BI  
 (179174-79-9/RN)  
 1 18343-90-3/BI  
 (18343-90-3/RN)  
 1 3068-00-6/BI  
 (3068-00-6/RN)  
 1 329900-75-6/BI  
 (329900-75-6/RN)  
 1 329967-85-3/BI  
 (329967-85-3/RN)  
 1 50-78-2/BI  
 (50-78-2/RN)  
 1 5048-26-0/BI  
 (5048-26-0/RN)  
 1 5754-34-7/BI  
 (5754-34-7/RN)  
 1 654068-92-5/BI  
 (654068-92-5/RN)  
 1 6835-50-3/BI  
 (6835-50-3/RN)  
 1 754242-03-0/BI  
 (754242-03-0/RN)  
 1 77-76-9/BI  
 (77-76-9/RN)  
 1 7761-88-8/BI  
 (7761-88-8/RN)  
 1 821-41-0/BI  
 (821-41-0/RN)  
 1 849139-06-6/BI  
 (849139-06-6/RN)  
 1 861405-26-7/BI  
 (861405-26-7/RN)  
 1 861405-28-9/BI  
 (861405-28-9/RN)  
 1 861405-33-6/BI  
 (861405-33-6/RN)  
 1 861405-34-7/BI  
 (861405-34-7/RN)  
 1 861655-83-6/BI  
 (861655-83-6/RN)  
 1 861655-84-7/BI  
 (861655-84-7/RN)  
 1 861655-85-8/BI  
 (861655-85-8/RN)  
 1 861655-86-9/BI  
 (861655-86-9/RN)

L5

34 (10102-43-9/BI OR 108-24-7/BI OR 122-04-3/BI OR 14739-12-9/BI  
 OR 14739-15-2/BI OR 14739-16-3/BI OR 14739-18-5/BI OR 14739-19-6  
 /BI OR 162011-90-7/BI OR 179174-76-6/BI OR 179174-77-7/BI OR  
 179174-79-9/BI OR 18343-90-3/BI OR 3068-00-6/BI OR 329900-75-6/B  
 I OR 329967-85-3/BI OR 50-78-2/BI OR 5048-26-0/BI OR 5754-34-7/B

I OR 654068-92-5/BI OR 6835-50-3/BI OR 754242-03-0/BI OR 77-76-9/BI OR 7761-88-8/BI OR 821-41-0/BI OR 849139-06-6/BI OR 861405-26-7/BI OR 861405-28-9/BI OR 861405-33-6/BI OR 861405-34-7/BI OR 861655-83-6/BI OR 861655-84-7/BI OR 861655-85-8/BI OR 861655-86-9/BI)

=> s 13 and 15

L6 4 L3 AND L5


=> d sca

L6 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 4,5-bis(nitrooxy)pentyl ester, ( $\alpha$ Z)-

MF C24 H26 N2 O12 S

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 3,4-bis(nitrooxy)butyl ester, ( $\alpha$ Z)-

MF C23 H24 N2 O12 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5,6-bis(nitrooxy)hexyl ester,  
( $\alpha$ Z)-  
MF C25 H28 N2 O12 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 4 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, (5R)-5,6-bis(nitrooxy)hexyl ester,  
( $\alpha$ Z)-  
MF C25 H28 N2 O12 S

Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file zcaplus\  
'ZCAPLUS\' IS NOT A VALID FILE NAME  
SESSION CONTINUES IN FILE 'REGISTRY'  
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files  
that are available. If you have requested multiple files, you can  
specify a corrected file name or you can enter "IGNORE" to continue  
accessing the remaining file names entered.

=> file zcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.40	209.76

FILE 'ZCAPLUS' ENTERED AT 11:18:58 ON 17 JUN 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS is  
strictly prohibited.

FILE COVERS 1907 - 17 Jun 2009 VOL 150 ISS 25  
FILE LAST UPDATED: 15 Jun 2009 (20090615/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

ZCAplus now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s l3  
L7 18 L3

=> s l7 and (nitrosated or nitrosylated)  
1340 NITROSATED  
604 NITROSYLATED  
L8 1 L7 AND (NITROSATED OR NITROSYLATED)

=> d sca

L8 1 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN  
IC ICM A61K031-40  
ICS A61K031-415; A61K031-421; A61K031-50; C07D207-325; C07D231-06;  
C07D237-14; C07D263-04; C07D263-06  
CC 21-2 (General Organic Chemistry)  
Section cross-reference(s): 1  
TI Preparation of nitrosated and nitrosylated

cyclooxygenase-2 inhibitors

ST cyclooxygenase 2 inhibitor nitrosated nitrosylated  
prepn

IT Analgesics  
Anti-inflammatory agents  
(preparation of nitrosated and nitrosylated  
cyclooxygenase-2 inhibitors)

IT Nitroso compounds  
Nitrosyl complexes  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of nitrosated and nitrosylated  
cyclooxygenase-2 inhibitors)

IT 329900-75-6, cyclooxygenase-2  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(mediated disorders; treatment; preparation of nitrosated and  
nitrosylated cyclooxygenase-2 inhibitors)

IT 205580-05-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT  
(Reactant or reagent); USES (Uses)  
(preparation of nitrosated and nitrosylated  
cyclooxygenase-2 inhibitors)

IT 346683-69-0P 346683-70-3P 346683-71-4P 346683-72-5P 346683-73-6P  
346683-75-8P 346683-76-9P 346683-77-0P 346683-78-1P 346683-79-2P  
346683-80-5P 346683-81-6P 346683-82-7P 346683-83-8P  
346683-84-9P 346683-85-0P 346683-86-1P 346683-87-2P 346683-88-3P  
347162-90-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of nitrosated and nitrosylated  
cyclooxygenase-2 inhibitors)

IT 346683-99-6P 346684-20-6P 346684-22-8P  
RL: BYP (Byproduct); PREP (Preparation)  
(preparation of nitrosated and nitrosylated  
cyclooxygenase-2 inhibitors)

IT 52-67-5, D-Penicillamine 53-86-1, Indomethacin 78-83-1,  
2-Methyl-1-propanol, reactions 78-94-4, Methyl vinyl ketone, reactions  
100-53-8, Benzyl mercaptan 627-18-9, 3-Bromo-1-propanol 1445-73-4,  
1-Methyl-4-piperidone 1778-09-2, 4-Methylthioacetophenone 2417-72-3,  
Methyl 4-bromomethylbenzoate 3446-89-7, 4-Methylthiobenzaldehyde  
18162-48-6, tert-Butyldimethylsilyl chloride 21382-98-9,  
4-Methylthiobenzonitrile 24214-73-1, Cyclohexylhydrazine hydrochloride  
32047-53-3, 1-Amino-2-methyl-2-propanethiol hydrochloride 61040-78-6,  
2,4,6-Trimethoxybenzyl alcohol 90878-19-6, Phenethylmagnesium chloride  
194596-99-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of nitrosated and nitrosylated  
cyclooxygenase-2 inhibitors)

IT 15581-80-3P 28399-82-8P 40027-88-1P 73303-88-5P,  
2-Methyl-2-mercapto-1-propanol 86864-60-0P 89031-84-5P 136881-95-3P  
157672-00-9P 170571-19-4P 170571-20-7P 170571-71-8P 179174-91-5P  
179174-92-6P 179174-93-7P 179174-94-8P 181695-72-7P 181695-81-8P  
189501-33-5P 189501-34-6P 205579-90-4P 213763-90-7P 213764-17-1P  
215124-07-5P 215124-20-2P 291518-72-4P 346683-89-4P 346683-90-7P  
346683-91-8P 346683-92-9P 346683-94-1P 346683-95-2P 346683-96-3P  
346683-97-4P 346683-98-5P 346684-00-2P 346684-01-3P 346684-02-4P  
346684-03-5P 346684-04-6P 346684-05-7P 346684-06-8P 346684-07-9P

346684-08-0P 346684-09-1P 346684-10-4P 346684-11-5P 346684-12-6P  
 346684-13-7P 346684-14-8P 346684-15-9P 346684-16-0P 346684-17-1P  
 346684-18-2P 346684-19-3P 346684-21-7P 347162-91-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of nitrosated and nitrosylated  
 cyclooxygenase-2 inhibitors)  
 IT 346684-23-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of nitrosated and nitrosylated  
 cyclooxygenase-2 inhibitors)

ALL ANSWERS HAVE BEEN SCANNED

=> s 17 and (nitrosated or nitrosylated or NO or (nitric (w) oxide))  
 1340 NITROSATED  
 604 NITROSYLATED  
 3932570 NO  
 220094 NOS  
 2032 NOES  
 4060112 NO  
 (NO OR NOS OR NOES)  
 223122 NITRIC  
 3 NITRICS  
 223125 NITRIC  
 (NITRIC OR NITRICS)  
 1991269 OXIDE  
 377613 OXIDES  
 2097881 OXIDE  
 (OXIDE OR OXIDES)  
 131578 NITRIC (W) OXIDE  
 L9 11 L7 AND (NITROSATED OR NITROSYLATED OR NO OR (NITRIC (W) OXIDE))

=> d sca

L9 11 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN  
 IC ICM C07C317-24  
 ICS A61K031-21  
 INCL 514509000; 558482000  
 CC 25-18 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)  
 Section cross-reference(s): 1  
 TI Process for making nitric oxide releasing prodrugs of  
 diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors  
 ST nitric oxide releasing prodrug diphenylbutenoate hexyl  
 nitrate  
 IT Drug delivery systems  
 (prodrugs; preparation of nitric oxide releasing  
 prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)  
 IT 329900-75-6, Cyclooxygenase 2  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; preparation of nitric oxide releasing  
 prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)  
 IT 10102-43-9, Nitric oxide, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of nitric oxide releasing prodrugs of  
 diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)  
 IT 64-19-7, Acetic acid, uses 67-68-5, DmsO, uses 68-12-2, Dmf, uses  
 75-05-8, Acetonitrile, uses 75-09-2, Dichloromethane, uses 75-52-5,  
 Nitromethane, uses 127-19-5, N,N-Dimethylacetamide 872-50-4,  
 1-Methyl-2-pyrrolidinone, uses 1300-21-6, Dichloroethane 25321-22-6,  
 Dichlorobenzene

RL: NUU (Other use, unclassified); USES (Uses)  
 (preparation of nitric oxide releasing prodrugs of  
 diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)

IT 937-14-4, m-Chloroperbenzoic acid 1504-58-1, 3-Phenyl-2-propyn-1-ol  
 4286-55-9 7722-84-1, Hydrogen peroxide, reactions 10058-23-8,  
 Potassium peroxymonosulfate 11138-47-9, Sodium perborate 74087-85-7,  
 Dimethyldioxirane 78948-87-5, Magnesium monoperoxyphthalate  
 210292-04-9, 4-Methylthiophenylmagnesium chloride  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of nitric oxide releasing prodrugs of  
 diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)

IT 176594-44-8P 179174-79-9P 754242-10-9P 754242-11-0P  
 754242-12-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of nitric oxide releasing prodrugs of  
 diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)

IT 754241-98-0P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)  
 (preparation of nitric oxide releasing prodrugs of  
 diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):  
 HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d ibib hitstr 1-11  
 THE ESTIMATED COST FOR THIS REQUEST IS 42.79 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L9 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:465556 ZCAPLUS  
 DOCUMENT NUMBER: 148:523285  
 TITLE: Development of a discriminating in vitro dissolution  
 method for a poorly soluble NO-donating  
 selective cyclooxygenase-2 inhibitor

AUTHOR(S): Papp, Robert; Luk, Pauline; Mullett, Wayne M.; Kwong,  
 Elizabeth; Debnath, Smita; Thibert, Roch

CORPORATE SOURCE: Drug Metabolism and Pharmacokinetics, Merck Frosst  
 Center for Therapeutic Research, Kirkland, QC, H9H  
 3L1, Can.

SOURCE: Journal of Pharmaceutical and Biomedical Analysis  
 (2008), 47(1), 16-22  
 CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


IT 754241-98-0  
 RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (development of discriminating in vitro dissoln. method for poorly soluble  
 NO-donating cyclooxygenase-2 inhibitor)

RN 754241-98-0 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-  
 (methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, ( $\alpha$ Z)-  
 (CA INDEX NAME)

Double bond geometry as shown.





REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:495882 ZCAPLUS

DOCUMENT NUMBER: 145:14695

TITLE: Compounds for targeting mechanisms implicated in the progression of stroke

INVENTOR(S): Munoz, Benito; Payne, Joseph E.; Prasit, Petpiboon; Reger, Thomas S.; Smith, Nicholas D.; Stock, Nicholas S.; McGuire, Angela R.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006055404	A2	20060526	WO 2005-US40851	20051110
WO 2006055404	A3	20060810		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-628280P P 20041116

OTHER SOURCE(S): MARPAT 145:14695

IT 887908-51-2P



RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(comps. for targeting mechanisms implicated in progression of stroke)

RN 887908-51-2 ZCAPLUS


CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 3-[[[(2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-2-oxopropyl ester (CA INDEX NAME)

Double bond geometry as shown.




IT 887908-54-5 887908-56-7  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comps. for targeting mechanisms implicated in progression of stroke)  
 RN 887908-54-5 ZCAPLUS  
 CN 1H-Benzimidazole-4-carboxylic acid,  
 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-,  
 (2Z)-3-(3,4-difluorophenyl)-4-ethoxy-2-[4-(methanesulfonyl)phenyl]-4-oxo-2-  
 buten-1-yl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 887908-56-7 ZCAPLUS  
 CN Ethanaminium, 2-[[ (2Z)-2-(3,4-difluorophenyl)-4-[[ (3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl]oxy]-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:383478 ZCAPLUS  
 DOCUMENT NUMBER: 144:432558  
 TITLE: Preparation of methylsulfonylphenylalkenoates as water soluble prodrugs of COX-2 inhibitors.  
 INVENTOR(S): Munoz, Benito; Payne, Joseph Edward; Prasit, Petpiboon; Reger, Thomas S.; Smith, Nicholas D.; Stock, Nicholas S.  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 60 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044230	A1	20060427	WO 2005-US36031	20051007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-617962P P 20041012

OTHER SOURCE(S): MARPAT 144:432558

IT 885020-33-7P 885020-34-8P 885020-36-0P  
 885020-37-1P 885020-38-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of methylsulfonylphenylalkenoates as water soluble

prodrugs of COX-2 inhibitors)

RN 885020-33-7 ZCAPLUS

CN Ethanaminium, 2-[[ (2Z)-4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 885020-34-8 ZCAPLUS

CN Ethanaminium, 2-[[ (2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 885020-36-0 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, ( $\alpha$ Z)-, (2S)-2-amino-3-ethoxy-3-oxopropyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 885020-35-9  
 CMF C24 H25 F2 N O8 S

Absolute stereochemistry.  
 Double bond geometry as shown.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 885020-37-1 ZCAPLUS  
 CN L-Aspartic acid, 4-[(2Z)-3-(3,4-difluorophenyl)-4-ethoxy-2-[4-(methylsulfonyl)phenyl]-4-oxo-2-buten-1-yl] ester (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 885020-38-2 ZCAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[2-[[ (2S)-2,6-diamino-1-oxohexyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, monoethyl ester, ( $\alpha$ E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




IT 885020-42-8P 885020-43-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of methylsulfonylphenylalkenoates as water soluble prodrugs of COX-2 inhibitors)  
RN 885020-42-8 ZCAPLUS  
CN Ethanaminium, 2-[[ (2Z)-4-(acetyloxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-, bromide (1:1) (CA INDEX NAME)

Double bond geometry as shown.




RN 885020-43-9 ZCAPLUS  
 CN Ethanaminium, 2-[[ (2Z)-4-(acetyloxy)-2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-oxo-2-buten-1-yl]oxy]-N,N,N-trimethyl-, bromide (1:1) (CA INDEX NAME)

Double bond geometry as shown.



IT 885020-47-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of methylsulfonylphenylalkenoates as water soluble prodrugs of COX-2 inhibitors)  
 RN 885020-47-3 ZCAPLUS  
 CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, (2S)-2-[[ (1,1-dimethylethoxy)carbonyl]amino]-3-ethoxy-3-oxopropyl ester, (αZ)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1315893 ZCAPLUS

DOCUMENT NUMBER: 144:212486

TITLE: Synthesis of a NO-Releasing Prodrug of Rofecoxib

AUTHOR(S): Engelhardt, F. Conrad; Shi, Yao-Jun; Cowden, Cameron J.; Conlon, David A.; Pipik, Brenda; Zhou, George; McNamara, James M.; Dolling, Ulf-H.

CORPORATE SOURCE: Department of Process Research, Merck Company, Rahway, NJ, 07065-0900, USA

SOURCE: Journal of Organic Chemistry (2006), 71(2), 480-491  
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:212486

IT 875783-67-8P


RL: BYP (Byproduct); PREP (Preparation)

(synthesis of a NO-releasing prodrug of rofecoxib in five chemical steps from 3-phenyl-2-propyn-1-ol)

RN 875783-67-8 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 1,6-hexanediyl ester, ( $\alpha$ Z, $\alpha'$ Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 754242-04-1P

RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of a NO-releasing prodrug of rofecoxib in five chemical steps from 3-phenyl-2-propyn-1-ol)


RN 754242-04-1 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-




(methylsulfonyl)phenyl]ethylidene]-, 6-bromohexyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 754242-12-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of a NO-releasing prodrug of rofecoxib in five chemical steps from 3-phenyl-2-propyn-1-ol)  
RN 754242-12-1 ZCAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-hydroxyhexyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 754241-98-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of a NO-releasing prodrug of rofecoxib in five chemical steps from 3-phenyl-2-propyn-1-ol)  
RN 754241-98-0 ZCAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:963804 ZCAPLUS

DOCUMENT NUMBER: 143:266677

TITLE: Process for making nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors

INVENTOR(S): Shi, Yao-Jun; Engelhardt, F. Conrad; Cowden, Cameron John; Conlon, David A.; Pipik, Brenda

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050192346	A1	20050901	US 2005-66676	20050225
PRIORITY APPLN. INFO.:			US 2004-549126P	P 20040301
OTHER SOURCE(S):			CASREACT 143:266677; MARPAT 143:266677	
IT 754242-12-1P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)				
RN 754242-12-1 ZCAPLUS				
CN Benzeneacetic acid, $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-hydroxyhexyl ester, ( $\alpha$ Z)- (CA INDEX NAME)				

Double bond geometry as shown.




IT 754241-98-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)

RN 754241-98-0 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, ( $\alpha$ Z)-  
(CA INDEX NAME)

Double bond geometry as shown.



L9 ANSWER 6 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:696873 ZCAPLUS

DOCUMENT NUMBER: 143:172624

TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors

INVENTOR(S): Dufresne, Claude; Berthelette, Carl; Li, Lianhai; Guay, Daniel; Gallant, Michel; Lacombe, Patrick; Aspiotis, Renee; Wang, Zhaoyin; Sturino, Claudio F.

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070883	A1	20050804	WO 2005-CA83	20050125
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005206228	A1	20050804	AU 2005-206228	20050125
CA 2554334	A1	20050804	CA 2005-2554334	20050125
EP 1711459	A1	20061018	EP 2005-706413	20050125
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1914169	A	20070214	CN 2005-80003263	20050125
JP 2007520483	T	20070726	JP 2006-549814	20050125

US 20080242643	A1	20081002	US 2006-586381	20060718
IN 2006DN04347	A	20070713	IN 2006-DN4347	20060727
PRIORITY APPLN. INFO.:			US 2004-539666P	P 20040127
			WO 2005-CA83	W 20050125

OTHER SOURCE(S): CASREACT 143:172624; MARPAT 143:172624


IT 861430-33-3P 861430-34-4P 861430-36-6P  
861430-38-8P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors)

RN 861430-33-3 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-[[[4,5-bis(nitrooxy)pentyl]oxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 861430-34-4 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-[[[4,5-bis(nitrooxy)pentyl]oxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 861430-36-6 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-[[[2,3-bis(nitrooxy)propoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 861430-38-8 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-[[[2,3-bis(nitrooxy)propoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, phenylmethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:696865 ZCAPLUS

DOCUMENT NUMBER: 143:193802

TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors

INVENTOR(S): Berthelette, Carl; Li, Lianhai; Beaulieu, Christian; Wang, Zhaoyin; Sturino, Claudio F.

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070874	A1	20050804	WO 2005-CA84	20050125
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005206229	A1	20050804	AU 2005-206229	20050125
CA 2554333	A1	20050804	CA 2005-2554333	20050125
EP 1711457	A1	20061018	EP 2005-706414	20050125
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1914151	A	20070214	CN 2005-80003240	20050125
JP 2007520484	T	20070726	JP 2006-549815	20050125
US 20080227758	A1	20080918	US 2006-586573	20060718
IN 2006DN04343	A	20070713	IN 2006-DN4343	20060727
PRIORITY APPLN. INFO.:			US 2004-540101P	P 20040127

## OTHER SOURCE(S):

CASREACT 143:193802; MARPAT 143:193802


IT 861655-83-6P 861655-84-7P 861655-85-8P  
861655-86-9P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors)

RN 861655-83-6 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5,6-bis(nitrooxy)hexyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 861655-84-7 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, (5R)-5,6-bis(nitrooxy)hexyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 861655-85-8 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 4,5-bis(nitrooxy)pentyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 861655-86-9 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 3,4-bis(nitrooxy)butyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:739958 ZCAPLUS

DOCUMENT NUMBER: 141:260542

TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as selective cyclooxygenase-2 inhibitors

INVENTOR(S): Berthelette, Carl; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin

PATENT ASSIGNEE(S): Merck Frosst Company, Can.

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040176331	A1	20040909	US 2004-790288	20040301
US 7169809	B2	20070130		
AU 2004240700	A1	20041202	AU 2004-240700	20040301
CA 2517490	A1	20041202	CA 2004-2517490	20040301
WO 2004103955	A1	20041202	WO 2004-CA314	20040301

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,



NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

EP 1601644 A1 20051207 EP 2004-761562 20040301

EP 1601644 B1 20090527

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

JP 2007516954 T 20070628 JP 2006-529472 20040301

PRIORITY APPLN. INFO.:

US 2003-452124P P 20030305

WO 2004-CA314 W 20040301

OTHER SOURCE(S): MARPAT 141:260542

IT 754241-98-0P 754241-99-1P 754242-00-7P

754242-01-8P 754242-02-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of nitric oxide releasing prodrugs of  
 diarylfuranones as selective COX-2 inhibitors)

RN 754241-98-0 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-  
 (methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, ( $\alpha$ Z)-  
 (CA INDEX NAME)


Double bond geometry as shown.



RN 754241-99-1 ZCAPLUS

CN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-  
 oxo-3-phenyl-2-butenyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 754242-00-7 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5-(nitrooxy)pentyl ester, ( $\alpha$ Z)-  
 (CA INDEX NAME)

Double bond geometry as shown.




RN 754242-01-8 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 7-(nitrooxy)heptyl ester, ( $\alpha$ Z)-  
 (CA INDEX NAME)

Double bond geometry as shown.




RN 754242-02-9 ZCAPLUS  
 CN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-buten-1-yl ester (CA INDEX NAME)

Double bond geometry as shown.




IT 754242-04-1P 754242-08-5P 754242-09-6P  
 754242-12-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of nitric oxide releasing prodrugs of  
 diarylfuranones as selective COX-2 inhibitors)  
 RN 754242-04-1 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-  
 (methylsulfonyl)phenyl]ethylidene]-, 6-bromohexyl ester, ( $\alpha$ Z)- (CA  
 INDEX NAME)

Double bond geometry as shown.



RN 754242-08-5 ZCAPLUS  
 CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,  
 (2Z)-4-[(6-bromohexyl)oxy]-2-[4-(methylsulfonyl)phenyl]-4-oxo-3-phenyl-2-  
 buten-1-yl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 754242-09-6 ZCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,  
(2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-buten-1-yl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 754242-12-1 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-hydroxyhexyl ester, ( $\alpha$ Z)-  
(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:101124 ZCAPLUS

DOCUMENT NUMBER: 140:163574

TITLE: Preparation of nitric oxide releasing diaryl-2-(5H)-furanone prodrugs as selective cyclooxygenase-2 inhibitors for treatment inflammatory diseases

INVENTOR(S): Berthelette, Carl; Lachance, Nicholas; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin; Young, Robert N.; Dufresne, Claude

PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011421	A1	20040205	WO 2003-CA1115	20030724
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2493082	A1	20040205	CA 2003-2493082	20030724
AU 2003252515	A1	20040216	AU 2003-252515	20030724
EP 1527045	A1	20050504	EP 2003-771010	20030724
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 20050261245	A1	20051124	US 2005-521075	20050112
US 7199154	B2	20070403		
PRIORITY APPLN. INFO.:			US 2002-398683P	P 20020726
			US 2002-435341P	P 20021220
			WO 2003-CA1115	W 20030724

OTHER SOURCE(S): CASREACT 140:163574; MARPAT 140:163574

IT 654069-14-4P


RL: BYP (Byproduct); PREP (Preparation)

(preparation of nitric oxide releasing diarylfuranone prodrugs as selective cyclooxygenase-2 inhibitors for treatment of inflammatory diseases)

RN 654069-14-4 ZCAPLUS


CN Benzeneacetic acid,  $\alpha$ -[2-[[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]benzoyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ E)- (CA INDEX NAME)

Double bond geometry as shown.




IT 654068-75-4P 654068-76-5P 654068-79-8P  
 654068-81-2P 654068-83-4P 654068-84-5P  
 654068-85-6P 654068-86-7P 654068-87-8P  
 654068-88-9P 654068-89-0P 654068-90-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of nitric oxide releasing diarylfuranone  
 prodrugs as selective cyclooxygenase-2 inhibitors for treatment of  
 inflammatory diseases)  
 RN 654068-75-4 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[3-  
 [(nitrooxy)methyl]benzoyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA  
 INDEX NAME)

Double bond geometry as shown.



RN 654068-76-5 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[4-  
 (nitrooxy)butoxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA  
 INDEX NAME)


Double bond geometry as shown.



RN 654068-79-8 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-1-oxohexyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 654068-81-2 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[4-(nitrooxy)butoxy]carbonyl]oxy]ethylidene]-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 654068-83-4 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[6-(nitrooxy)hexyl]oxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)-

(CA INDEX NAME)


Double bond geometry as shown.



RN 654068-84-5 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[6-(nitrooxy)hexyl]oxy]carbonyl]oxy]ethylidene]-, ethyl ester, ( $\alpha$ Z)-  
(CA INDEX NAME)


Double bond geometry as shown.



RN 654068-85-6 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-1-oxohexyl]oxy]ethylidene]-, 2-(diethylamino)ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.






RN 654068-86-7 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-1-oxohexyl]oxy]ethylidene]-, (1S)-2-(1,1-dimethylethoxy)-1-methyl-2-oxoethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 654068-87-8 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[6-(nitrooxy)-1-oxohexyl]oxy]ethylidene]-, (1S)-1-carboxyethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 654068-88-9 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[5-(nitrooxy)pentyl]oxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 654068-89-0 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[5-(nitrooxy)pentyl]oxy]carbonyl]oxy]ethylidene]-, 2-(diethylamino)ethyl ester, hydrochloride (1:1), ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 654068-90-3 ZCAPLUS


CN Benzeneacetic acid,  $\alpha$ -[1-[4-(methylsulfonyl)phenyl]-2-[[[3-[(nitrooxy)methyl]phenoxy]carbonyl]oxy]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 654068-91-4P 654068-95-8P 654068-98-1P  
 654069-03-1P 654069-09-7P 654069-10-0P  
 654069-11-1P 654069-15-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of nitric oxide releasing diarylfuranone  
 prodrugs as selective cyclooxygenase-2 inhibitors for treatment of  
 inflammatory diseases)  
 RN 654068-91-4 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-[[3-[[[(1,1-  
 dimethylethyl)dimethylsilyl]oxy]methyl]benzoyl]oxy]-1-[4-  
 (methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX  
 NAME)

Double bond geometry as shown.




RN 654068-95-8 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-[[4-bromobutoxy)carbonyl]oxy]-1-[4-  
 (methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX  
 NAME)

Double bond geometry as shown.




RN 654068-98-1 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-[[[(4-bromobutoxy)carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 654069-03-1 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-[[[(6-bromohexyl)oxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 654069-09-7 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-[[[3-[[[(1,1-

dimethylethyl)dimethylsilyl]oxy)methyl]phenoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 654069-10-0 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-[[[3-(hydroxymethyl)phenoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 654069-11-1 ZCAPLUS


CN Benzeneacetic acid,  $\alpha$ -[2-[[[3-(bromomethyl)phenoxy]carbonyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 654069-15-5 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-[[3-(bromomethyl)benzoyl]oxy]-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:472491 ZCAPLUS  
 DOCUMENT NUMBER: 135:76524  
 TITLE: Preparation of nitrosated and nitrosylated cyclooxygenase-2 inhibitors  
 INVENTOR(S): Bandarage, Ramani R.; Bandarage, Upul K.; Fang, Xinqin; Garvey, David S.; Letts, L. Gordon; Schroeder, Joseph D.; Tam, Sang William  
 PATENT ASSIGNEE(S): Nitromed, Inc., USA  
 SOURCE: PCT Int. Appl., 230 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045703	A1	20010628	WO 2000-US35014	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


CA 2393724	A1	20010628	CA 2000-2393724	20001222
US 20010041726	A1	20011115	US 2000-741816	20001222
US 6649629	B2	20031118		
EP 1246621	A1	20021009	EP 2000-989422	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017037	A	20030610	BR 2000-17037	20001222
JP 2003523958	T	20030812	JP 2001-546642	20001222
NZ 519781	A	20040430	NZ 2000-519781	20001222
AU 782971	B2	20050915	AU 2001-25928	20001222
MX 2002006312	A	20040621	MX 2002-6312	20020624
ZA 2002005707	A	20031111	ZA 2002-5707	20020717
US 20030220228	A1	20031127	US 2003-463671	20030618
US 7166618	B2	20070123		
US 20070060571	A1	20070315	US 2006-599519	20061115
US 7432285	B2	20081007		
US 20090099139	A1	20090416	US 2008-196184	20080821
PRIORITY APPLN. INFO.:				
			US 1999-171623P	P 19991223
			US 2000-226085P	P 20000818
			US 2000-741816	A3 20001222
			WO 2000-US35014	W 20001222
			US 2003-463671	A3 20030618
			US 2006-599519	A3 20061115
OTHER SOURCE(S): MARPAT 135:76524				
IT	346683-81-6P 346683-83-8P			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of nitrosated and nitrosylated cyclooxygenase-2 inhibitors)			
RN	346683-81-6 ZCAPLUS			
CN	Benzeneacetic acid, $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-, 3-[4-[1-methyl-1-(nitrosothio)ethyl]-2-oxo-3-oxazolidinyl]propyl ester, ( $\alpha$ Z)- (CA INDEX NAME)			

Double bond geometry as shown.



RN 346683-83-8 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-,  
 2-[1-methyl-4-(nitrosothio)-4-piperidinyl]ethyl ester, ( $\alpha$ Z)- (CA  
 INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:462317 ZCAPLUS  
 DOCUMENT NUMBER: 125:114294  
 ORIGINAL REFERENCE NO.: 125:21435a, 21438a  
 TITLE: Preparation of stilbene derivatives useful as  
 cyclooxygenase-2 inhibitors  
 INVENTOR(S): Atkinson, Joseph G.; Wang, Zhaoyin  
 PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.  
 SOURCE: PCT Int. Appl., 80 pp.




CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613483	A1	19960509	WO 1995-CA601	19951024
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2200462	A1	19960509	CA 1995-2200462	19951024
AU 9536950	A	19960523	AU 1995-36950	19951024
AU 688980	B2	19980319		
EP 788476	A1	19970813	EP 1995-944787	19951024
EP 788476	B1	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10507765	T	19980728	JP 1995-514204	19951024
AT 185797	T	19991115	AT 1995-944787	19951024
ES 2139959	T3	20000216	ES 1995-944787	19951024
US 5849943	A	19981215	US 1997-817128	19970407
PRIORITY APPLN. INFO.:			US 1994-330172	A1 19941027
			WO 1995-CA601	W 19951024

OTHER SOURCE(S): MARPAT 125:114294


IT 179174-84-6P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of stilbene derivs. useful as cyclooxygenase-2 inhibitors)  
RN 179174-84-6 ZCAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 179174-89-1 179174-90-4 179174-95-9  
179175-00-9 179175-04-3 179175-09-8  
179175-14-5  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of stilbene derivs. useful as cyclooxygenase-2 inhibitors)  
RN 179174-89-1 ZCAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[2-(benzoyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179174-90-4 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-3,4-difluoro-, methyl ester, (Z)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 179174-95-9 ZCAPLUS

CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-4-fluoro-, methyl ester, (Z)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 179175-00-9 ZCAPLUS


CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179175-04-3 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[1-[4-(aminosulfonyl)phenyl]-2-(benzoyloxy)ethylidene]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179175-09-8 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(aminosulfonyl)phenyl]ethylidene]-3,4-difluoro-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179175-14-5 ZCAPLUS  
 CN Benzeneacetic acid,  $\alpha$ -[2-(acetyloxy)-1-[4-(aminosulfonyl)phenyl]ethylidene]-4-fluoro-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:54:15 ON 17 JUN 2009)

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 17 JUN 2009

L1 STRUCTURE UPLOADED  
L2 4 S SAM SSS L1  
L3 84 S FULL SSS L1

FILE 'ZCAPLUS' ENTERED AT 11:14:23 ON 17 JUN 2009

E US2006-586573/APPS  
L4 1 S US2006-586573/APPS  
SEL RN

FILE 'REGISTRY' ENTERED AT 11:15:49 ON 17 JUN 2009

L5 34 S E1-E34  
L6 4 S L3 AND L5

FILE 'ZCAPLUS' ENTERED AT 11:18:58 ON 17 JUN 2009

L7 18 S L3  
L8 1 S L7 AND (NITROSATED OR NITROSYLATED)  
L9 11 S L7 AND (NITROSATED OR NITROSYLATED OR NO OR (NITRIC (W) OXIDE

=> exit

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
67.29	277.05

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 11:59:21 ON 17 JUN 2009